Migraine – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Acute Migraine (US)
Questions answered
- What patient shares do key acute therapies and brands garner by line of therapy in newly diagnosed migraine patients? What are the quarterly trends in prescribing of acute therapies among recently treated and newly diagnosed migraine patients?
- How have oral CGRP receptor antagonists been integrated into the acute treatment algorithm, and what is their source of business?
- What percentage of migraine patients receive acute drug therapy within two years of diagnosis, and how quickly? What percentage of patients progress to later lines of acute therapy within two years of diagnosis?
- What percentage of migraine patients are treated with acute monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level persistency rates for acute therapies among drug-treated patients?
Markets covered: United States.
Key companies: Pfizer, AbbVie, Eli Lilly, Scilex, Impel Pharmaceuticals, GlaxoSmithKline, Merck & Co.
Key drugs: Ubrelvy, Nurtec ODT, Reyvow, Elyxyb, Trudhesa, Zembrace SymTouch, Onzetra Xsail, sumatriptan, zolmitriptan, rizatriptan, and other FDA-approved acute antimigraine therapies
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Ankita Sharma, M.B.A., Manager, Healthcare Research & Data Analytics, CNS/Ophthalmology Disorders. Ankita’s focus is the epilepsy market. Prior to joining the company, she was a knowledge management manager at ZS Associates. She received her M.B.A. in hospital and healthcare administration from Symbiosis International University in India.
Andrea S. Witt, Ph.D., is Director of the Central Nervous System and Ophthalmology Disorders Portfolio at Clarivate, where she oversees a team of Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.
Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her Ph.D. degree.